Publicacions (24) Publicacions de Manuel Munuera Cabeza

2023

  1. Actin Polymerization Defects Induce Mitochondrial Dysfunction in Cellular Models of Nemaline Myopathies

    Antioxidants, Vol. 12, Núm. 12

  2. Alpha-lipoic acid supplementation corrects pathological alterations in cellular models of pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels

    Orphanet journal of rare diseases, Vol. 18, Núm. 1, pp. 80

  3. Antioxidants Prevent Iron Accumulation and Lipid Peroxidation, but Do Not Correct Autophagy Dysfunction or Mitochondrial Bioenergetics in Cellular Models of BPAN

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  4. Mitochondrial Quality Control via Mitochondrial Unfolded Protein Response (mtUPR) in Ageing and Neurodegenerative Diseases

    Biomolecules, Vol. 13, Núm. 12

  5. Neurodegeneration, Mitochondria, and Antibiotics

    Metabolites, Vol. 13, Núm. 3

  6. Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration

    Pharmaceuticals, Vol. 16, Núm. 10

  7. Vicious cycle of lipid peroxidation and iron accumulation in neurodegeneration

    Neural Regeneration Research, Vol. 18, Núm. 6, pp. 1196-1202

  8. mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Activation of the Mitochondrial Unfolded Protein Response: A New Therapeutic Target?

    Biomedicines, Vol. 10, Núm. 7

  2. Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome

    Genes, Vol. 13, Núm. 12

  3. Pterostilbene in Combination With Mitochondrial Cofactors Improve Mitochondrial Function in Cellular Models of Mitochondrial Diseases

    Frontiers in Pharmacology, Vol. 13

  4. Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels

    Orphanet journal of rare diseases, Vol. 17, Núm. 1, pp. 311

  5. UPRmt activation improves pathological alterations in cellular models of mitochondrial diseases

    Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1

  6. Vitamin E prevents lipid peroxidation and iron accumulation in PLA2G6-Associated Neurodegeneration

    Neurobiology of Disease, Vol. 165

2021

  1. Coenzyme q10 analogues: Benefits and challenges for therapeutics

    Antioxidants, Vol. 10, Núm. 2, pp. 1-20

  2. Down regulation of the expression of mitochondrial phosphopantetheinyl-proteins in pantothenate kinase-associated neurodegeneration: pathophysiological consequences and therapeutic perspectives

    Orphanet Journal of Rare Diseases, Vol. 16, Núm. 1

  3. From mitochondria to atherosclerosis: The inflammation path

    Biomedicines, Vol. 9, Núm. 3, pp. 1-24

  4. Mitochondria and antibiotics: For good or for evil?

    Biomolecules, Vol. 11, Núm. 7

  5. Mitochondrial membrane Protein-Associated Neurodegeneration (MPAN): Pathophysiological characterization and pharmacological screening for potential therapies.

    Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, Núm. 10

2020

  1. Advances in mt-tRNA Mutation-Caused Mitochondrial Disease Modeling: Patients’ Brain in a Dish

    Frontiers in Genetics, Vol. 11